BVMF
BLAU3
Market cap467mUSD
Jul 09, Last price
10.35BRL
1D
-0.38%
1Q
-8.73%
IPO
-73.70%
Name
Blau Farmaceutica SA
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Blau FarmacĂȘutica S.A. operates as a pharmaceutical enterprise, supplying private label medications across Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay. Its extensive product portfolio encompasses a broad spectrum of therapeutic areas, including immunology, hematology, oncology, nephrology, specialized treatments, and antibiotics. The company's offerings also extend to biological drugs, oral and injectable therapies for cancer, specialized treatments for infectious diseases, and a range of prescription and over-the-counter products like dermo-medicines and contraceptives, catering to both retail and non-retail markets. Additionally, Blau provides pharmaceuticals derived from blood, biological and biotechnological agents, and antiretroviral drugs. Its client base includes hospitals, private medical clinics, chemotherapy and hemodialysis centers, and public health institutions. Established in 1987, the firm's corporate headquarters are situated in Cotia, Brazil.
Valuation
Title BRL in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||